2596. Title: The Dynamics Of Invasive Pneumococcal Disease (IPD) due to <i>Streptococcus pneumoniae</i> and Impact Of Pneumococcal Conjugate Vaccines (PCVs) In Canada From 2000-2019
Notice bibliographique
Résumé
Abstract Background IPD remains a major cause of morbidity and mortality globally despite the implementation of PCVs in childhood immunization programs, due to the emergence of non-vaccine serotypes (NVTs) and persisting vaccine types. Newly approved vaccines such as PCV15 and PCV20 may address some of these issues. This study aimed to describe the epidemiology of IPD in Canada from 2000-2019 after PCV7 and PCV13 approval in 2001 and 2010, respectively, and evaluate the potential future impact of PCV15 and PCV20. Methods Data were collected from IPD cases in children and adults captured by the Pneumococcal Reference Laboratory in Alberta and the National Microbiology Lab during 2000-2019; this includes the majority of isolates from IPD across Canada, excluding Quebec. We calculated annual age-, and serotype-specific incidence rates and serotype distribution using population estimates from Statistics Canada. Results A total of 37,921 isolates from IPD cases were included in the analyses. After PCV7 introduction, IPD due to PCV7 serotypes decreased by 64% (2.2 to 0.8 cases per 100,000 population per year) from 2001 to 2010, while PCV13/non-PCV7 serotypes increased between 2004 and 2010 from 1.0 to 3.8 per 100,000 per year. After PCV13 introduction, IPD due to PCV13/non-PCV7 serotypes decreased by 53% (3.8 to 1.8 per 100,000 per year) between 2010 and 2019. The overall rate initially decreased from 8.7 to 7.6 per 100,000 between 2010-2014 but increased to 9.6 per 100,000 in 2019. From 2010 to 2019, IPD incidence increased by 63% (0.8 to 1.3 per 100,000 per year) for PCV15/non-PCV13 serotypes and by 33% (1.2 to 1.6 per 100,000) for PCV20/non-PCV15 serotypes. The proportion of serotypes in 2019 covered by PCV15 and PCV20 was 32% and 45% in infants aged &lt; 2 years and 43% and 56% in adults aged ≥65 years, respectively. There was an increased IPD burden observed for some PCV13 serotypes: serotype 3 increased from 0.7 to 1.1 per 100,000 per year between 2010 and 2019 and serotype 4 increased from 0.2 to 0.8 per 100,000 per year between 2014 and 2019. Conclusion IPD rates in Canada continue to increase despite the widespread use of PCV13. While PCV15 and PCV20 hold promise in addressing prevalent recently circulating serotypes, there remains a need to develop vaccines with broader coverage considering the constant emergence of NVTs. Disclosures Nirma Khatri Vadlamudi, PhD, MPH, Pfizer Canada: Grant/Research Support Greg Tyrrell, PhD, Merck Canada: Advisor/Consultant|Merck Canada: Grant/Research Support Manish Sadarangani, BM BCh, FRCPC, DPhil, GlaxoSmithKline: Grant/Research Support|Merck: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support|Sanofi Pasteur: Grant/Research Support|Seqirus: Grant/Research Support|Symvivo: Grant/Research Support|VBI Vaccines: Grant/Research Support
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».